Current Report Filing (8-k)
April 01 2022 - 10:26AM
Edgar (US Regulatory)
0001353406
false
0001353406
2022-03-30
2022-03-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): March 30, 2022
REDHAWK
HOLDINGS CORP.
(Exact
name of registrant as specified in its charter)
Nevada |
000-54323 |
20-3866475 |
(State or other jurisdiction
of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification
No.) |
|
|
|
100
Petroleum Drive, Suite 200,Lafayette,
Louisiana 70508 |
(Address
of principal executive offices) (Zip Code) |
Registrant’s
telephone number, including area code: (337) 269-5933
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: None.
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 |
Entry into Material Definitive Agreement. |
The
Registrant announced today that it agreed to now offer for sale vacuum blood collection tubes (“VBCT”).
A
VBCT is a glass or plastic test tube with a colored rubber stopper that creates a vacuum seal inside of the tube, facilitating the drawing
of a predetermined volume of liquid. VBCT may contain additives designed to stabilize and preserve the specimen prior to analytical testing.
VBCT are available with a safety-engineered stopper, with a variety of labeling options and draw volumes.
When
a VBCT is inserted into the clear plastic sheath attached to the blood collection tube, its rubber cap is punctured by an inner needle
and the vacuum in the tube pulls blood through the needle and into the VBCT. The filled VBCT is then removed, and another can be inserted
and filled the same way. The amount of air evacuated from the VBCT predetermines how much blood will fill the VBCT before blood stops
flowing.
VBCT
often include additives that mix with the blood when collected. Each VBCT is topped with a color-coded plastic or rubber cap, and the
color of each tube's plastic cap indicates which additives it contains. The meanings of the various VBCT colors are standardized across
manufacturers.
The
additives in the VBCT may include anticoagulants (EDTA, sodium citrate, heparin) or a gel with density between those
of blood cells and blood plasma. Additionally, some VBCT contain additives that preserve certain components of or substances
within the blood, such as glucose. When a VBCT is centrifuged, the materials within are separated by density, with the blood cells
sinking to the bottom and the plasma or serum accumulating at the top. Tubes containing gel can be easily handled and transported after
centrifugation without the blood cells and serum mixing.
VBCT
may contain additional substances that preserve blood for processing in a medical laboratory. Using the wrong VBCT may make the blood
sample unusable for the intended purpose. These additives are typically thin film coatings applied by the factory using an ultrasonic
nozzle.
The
shelf life of the VBCT expire over time because the vacuum is lost, and blood will not be drawn into the tube when the needle punctures
the cap.
VBCT
are also used as a medium to transport COVID-19 test specimens to PCR testing laboratories and are among the basic medical supplies taken
by disaster relief programs to affected area.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by
the undersigned, hereunto duly authorized.
|
REDHAWK HOLDINGS CORP. |
|
|
Date: April 1, 2022 |
By: |
/s/
G. Darcy Klug |
|
|
G. Darcy Klug |
|
|
Chief Financial Officer |
RedHawk (CE) (USOTC:SNDD)
Historical Stock Chart
From Mar 2024 to Apr 2024
RedHawk (CE) (USOTC:SNDD)
Historical Stock Chart
From Apr 2023 to Apr 2024